| Diabetes Mellitus, Non-Insulin-Dependent
Steglujan vs Tradjenta
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Steglujan vs Tradjenta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTradjenta has a higher rate of injection site reactions vs Steglujan based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tradjenta but not Steglujan, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Steglujan
Tradjenta
At A Glance
Oral
Once daily
SGLT2 inhibitor + DPP-4 inhibitor
Oral
Daily
DPP-4 inhibitor
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Starting dose 5 mg ertugliflozin/100 mg sitagliptin orally once daily in the morning, with or without food; may increase to 15 mg/100 mg once daily for additional glycemic control; not recommended if eGFR less than 45 mL/min/1.73 m2; withhold at least 4 days before surgery or procedures associated with prolonged fasting.
Diabetes Mellitus, Non-Insulin-Dependent 5 mg orally once daily, with or without food.
Contraindications
- Severe renal impairment (eGFR less than 30 mL/min/1.73 m2), end-stage renal disease (ESRD), or on dialysis
- Hypersensitivity to sitagliptin, ertugliflozin, or any excipient in STEGLUJAN
- Hypersensitivity to linagliptin or any excipient in TRADJENTA, including reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity
Adverse Reactions
Most common (>=2%) Female genital mycotic infections, male genital mycotic infections, urinary tract infections, headache, vaginal pruritus, increased urination, nasopharyngitis, back pain, weight decreased, thirst
Serious Diabetic ketoacidosis, pancreatitis, lower limb amputation, acute renal failure, volume depletion, urosepsis and pyelonephritis, heart failure, hypoglycemia (with insulin or insulin secretagogues), necrotizing fasciitis of the perineum (Fournier's Gangrene), hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid
Postmarketing Necrotizing fasciitis of the perineum, angioedema, rash, anaphylaxis, urticaria, cutaneous vasculitis, Stevens-Johnson syndrome, pruritus, hepatic enzyme elevations, acute pancreatitis, worsening renal function, severe and disabling arthralgia, myalgia, rhabdomyolysis
Most common (>=2%) Nasopharyngitis, diarrhea, cough
Serious Pancreatitis, hypoglycemia with concomitant insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, severe and disabling arthralgia, bullous pemphigoid, rash
Pharmacology
STEGLUJAN combines ertugliflozin, an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose and increases urinary glucose excretion, and sitagliptin, a DPP-4 inhibitor that slows inactivation of incretin hormones (GLP-1 and GIP), thereby increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner.
DPP-4 inhibitor; linagliptin reversibly inhibits DPP-4, the enzyme that degrades incretin hormones GLP-1 and GIP, thereby increasing active incretin concentrations, stimulating glucose-dependent insulin release from pancreatic beta cells, and reducing glucagon secretion from pancreatic alpha-cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Steglujan
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (7/12) · Qty limit (9/12)
Tradjenta
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Steglujan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tradjenta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Steglujan
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Tradjenta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Steglujan.
No savings programs available for Tradjenta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SteglujanView full Steglujan profile
TradjentaView full Tradjenta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.